ERBB2 and neoplasm: Key eligibility criteria were: basal-like BC (estrogen and progesterone receptor < 1%, HER2-negative, cytokeratin 5/6 or epidermal growth factor receptor positive by immunohistochemistry), tumor size > 2 cm or <2 cm with nodal involvement [20].